Regulated Expression of Lentivirus-Mediated GDNF in Human Bone Marrow-Derived Mesenchymal Stem Cells and Its Neuroprotection on Dopaminergic Cells In Vitro
Authors:
Open Access
- 22 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e64389
Abstract
Gene regulation remains one of the major challenges for gene therapy in clinical trials. In the present study, we first generated a binary tetracycline-on (Tet-On) system based on two lentivirus vectors, one expressing both human glial cell line-derived neurotrophic factor (hGDNF) and humanized recombinant green fluorescent protein (hrGFP) genes under second-generation tetracycline response element (TRE), and the other expressing the advanced reverse tetracycline-controlled transactivator - rtTA2S-M2 under a human minimal cytomegalovirus immediate early (CMV-IE) promoter. This system allows simultaneous expression of hGDNF and hrGFP genes in the presence of doxycycline (Dox). Human bone marrow-derived mesenchymal stem cells (hMSCs) were transduced with the binary Tet-On lentivirus vectors and characterized in vitro in the presence (On) or absence (Off) of Dox. The expression of hGDNF and hrGFP transgenes in transduced hMSCs was tightly regulated as determined by flow cytometry (FCM), GDNF enzyme-linked immunosorbent assay (ELISA) and quantitative real time-polymerase chain reaction (qRT-PCR). There was a dose-dependent regulation for hrGFP transgene expression. The levels of hGDNF protein in culture medium were correlated with the mean fluorescence intensity (MFI) units of hrGFP. The levels of transgene background expression were very low in the absence of Dox. The treatment of the conditioned medium from cultures of transduced hMSCs in the presence of Dox protected SH-SY5Y cells against 6-hydroxydopamine (6-OHDA) toxicity as determined by cell viability using 3, [4,5-dimethylthiazol-2-yl]- diphenyltetrazolium bromide (MTT) assay. The treatment of the conditioned medium was also found to improve the survival of dopaminergic (DA) neurons of ventral mesencephalic (VM) tissue in serum-free culture conditions as assessed by cell body area, the number of neurites and dendrite branching points, and proportion of tyrosine hydroxylase (TH)-immunoreactive (IR) cells. Our inducible lentivirus-mediated hGDNF gene delivery system may provide useful tools for basic research on gene therapy for chronic neurological disorders such as Parkinson’s disease (PD).Keywords
This publication has 56 references indexed in Scilit:
- An Improved Tet-On System for Gene Expression in Neurons Delivered by a Single Lentiviral VectorHuman Gene Therapy, 2009
- Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primatesGene Therapy, 2005
- Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's diseaseEuropean Journal of Neuroscience, 2005
- Second‐generation tetracycline‐regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakinessThe Journal of Gene Medicine, 2004
- A Single Lentivirus Vector Mediates Doxycycline-Regulated Expression of Transgenes in the BrainHuman Gene Therapy, 2004
- Neurospheres modified to produce glial cell line‐derived neurotrophic factor increase the survival of transplanted dopamine neuronsJournal of Neuroscience Research, 2002
- Astrocyte Delivery of Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's DiseaseExperimental Neurology, 2002
- Robust and Efficient Regulation of Transgene Expression in Vivo by Improved Tetracycline-Dependent Lentiviral VectorsMolecular Therapy, 2002
- Lentiviral Vectors: Regulated Gene ExpressionMolecular Therapy, 2000
- GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic NeuronsScience, 1993